SCHEMBL9604465

SCHEMBL9604465

C=CCCCCCCCCOC1OC(COC2OC(COC(=O)c3ccccc3)C(C)C(C)C2C)C(C)C(OC2OC(COC(=O)c3ccccc3)C(C)C(C)C2C)C1OC(C)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.34
TSHR P16473 1/20 0.33
PAX8 Q06710 1/20 0.33
PRKCA P17252 1/20 0.32
AKT1 P31749 1/20 0.32
PTK2 Q05397 1/20 0.32
ALDH1A1 P00352 2/20 0.32
CYP2D6 P10635 1/20 0.32
MAPK1 P28482 1/20 0.32
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
POLB P06746 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
CA14 Q9ULX7 1/20 0.31
SLC2A1 P11166 1/20 0.31
PTPN1 P18031 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19767542 0.93 PAX8 (0.36) LMNATSHRPAX8PRKCAAKT1
SCHEMBL19767534 0.92 KMT2A (0.36) LMNATSHRPAX8PRKCAAKT1
SCHEMBL9604595 0.90 LMNA (0.35) LMNATSHRPAX8PRKCAAKT1
SCHEMBL16299440 0.89 PTPN1 (0.37) LMNATSHRPAX8PRKCAAKT1
SCHEMBL9604606 0.89 ALDH1A1 (0.35) LMNAPRKCAALDH1A1MAPK1KMT2A
SCHEMBL9604640 0.87 SLC2A1 (0.37) PRKCAALDH1A1SLC2A1TDP1
SCHEMBL9604605 0.87 PTPN1 (0.34) LMNAPAX8PRKCAAKT1PTK2
SCHEMBL18349826 0.87 TDP1 (0.40) LMNAALDH1A1CYP2D6MAPK1POLB
SCHEMBL10177687 0.86 TSHR (0.41) LMNATSHRPAX8PRKCAAKT1
SCHEMBL15833441 0.86 PAX8 (0.37) LMNATSHRPAX8PRKCAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-06 US disclosed
US-9814777-B2 Targeting lipids ARBUTUS BIOPHARMA CORPORATION (CA) 2017-11-14 US disclosed
US-20160375137-A9 TARGETING LIPIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2016-12-29 US disclosed
US-9370582-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9370581-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-06-21 US disclosed
US-9352048-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9290760-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-03-22 US disclosed
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-04-30 US disclosed
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides BANK OF AMERICA, N.A. 2015-01-08 US disclosed
US-8828956-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2014-09-09 US disclosed
US-20140179761-A1 TARGETING LIPIDS TEKMIRA PHARMACEUTICALS CORPORATION (CA) 2014-06-26 US disclosed
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2013-07-11 US disclosed
US-8450467-B2 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC (US) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178512-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC LMNA 266/4885TSHR 544/4885PAX8 1006/4885
US-20150119445-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC LMNA 271/4885TSHR 526/4885PAX8 1042/4885
US-20140179761-A1 TARGETING LIPIDS LY96, ABHD10, APOB LMNA 169/4885TSHR 2940/4885PAX8 4314/4885
US-11666653-B2 Carbohydrate conjugates as delivery agents for oligonucleotides HAVCR2, B3GAT3, CSGALNACT1 LMNA 1934/4885TSHR 991/4885PAX8 2815/4885
US-20150011615-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC LMNA 274/4885TSHR 535/4885PAX8 1029/4885
US-20150119444-A1 Carbohydrate Conjugates as Delivery Agents for Oligonucleotides LPXN, ZYX, OSTC LMNA 274/4885TSHR 535/4885PAX8 1029/4885
US-20120136042-A1 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES LPXN, ZYX, OSTC LMNA 266/4885TSHR 544/4885PAX8 1006/4885
US-20160375137-A9 TARGETING LIPIDS LY96, ABHD10, APOB LMNA 169/4885TSHR 2940/4885PAX8 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.